AstraZeneca Tagrisso Drug In Combination With Chemo Showed Strong Improvement In Trial
By Christian Moess Laursen
AstraZeneca said Wednesday that trial results showed that its Tagrisso drug in combination with chemotherapy demonstrated strong improvement for patients with lung cancer
The Anglo-Swedish pharmaceutical company said the FLAURA2 Phase 3 trial was for progression-free survival--the length of time a patient lives with a disease without it getting worse--for patients with epidermal growth factor receptor-mutated, non-small cell lung cancer.
For the moment, the overall survival data--the length of time from the start of diagnosis or treatment that the patient is still alive--were still immature and will be formally assessed at a subsequent analysis, AstraZeneca said.
"These significant FLAURA2 results show Tagrisso has the potential to offer patients in the first-line setting a new treatment option that can extend the time they live without their disease progressing," Executive Vice President of the company's Oncology R&D Susan Galbraith said.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
May 17, 2023 03:06 ET (07:06 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth